about
sameAs
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionHealth Outcomes in Acromegaly: Depression and Anxiety are Promising Targets for Improving Reduced Quality of Life.Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trialAnthropometric factors have significant influence on the outcome of the GHRH-arginine test: establishment of normative data for an automated immunoassay specifically measuring 22 kDa human growth hormone.Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.Clinical review: Outcome of bilateral adrenalectomy in Cushing's syndrome: a systematic review.Emerging drugs for acromegaly.A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome.Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry.Cushing's syndrome: a model for sarcopenic obesity.Assessment of lung function in a large cohort of patients with acromegaly.Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?Cystic Craniopharyngiomas: Microsurgical or Stereotactic Treatment?The Incidence of Cancer Among Acromegaly Patients: Results From the German Acromegaly Registry.Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey.
P50
Q33595081-4AB899BC-53BE-4F46-AA0F-962162EA699CQ34840936-9890BCBB-16B9-4166-88E8-40E32BB85212Q36030010-7B605C83-3B8A-44C7-8A59-D77753973982Q36216753-B662D6DC-01A1-4A31-8D7C-0CD46442B1F8Q37617510-6BC2F68D-0ADB-46E0-AE7A-CEC7CE04D17AQ38129854-71B2624E-D570-475D-A264-3B380616EDCAQ38176659-B5B7C62E-6836-4A0C-AF34-0C0670EC228AQ38494654-163C735C-923E-4396-8935-493342B2F9DFQ38624632-D2C6EA76-582B-4C70-9C77-A01E9CF7FE1CQ38681552-4F4472DB-AC35-4C6A-AF92-BE75999DB786Q38825742-6970CEAD-D543-450F-A8CC-794C53687B8FQ38852829-D05D4B00-66C1-42E0-84A9-EFE6FF638E0DQ39101582-E3B08041-7A63-4DAD-B912-58C9421C7DDFQ40658500-73390982-D75C-4E47-89C4-EBF13A45EACDQ41563475-2183660D-6817-4004-8565-2805ACFFEE5C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jochen Schopohl
@ast
Jochen Schopohl
@en
Jochen Schopohl
@es
Jochen Schopohl
@nl
Jochen Schopohl
@sl
type
label
Jochen Schopohl
@ast
Jochen Schopohl
@en
Jochen Schopohl
@es
Jochen Schopohl
@nl
Jochen Schopohl
@sl
prefLabel
Jochen Schopohl
@ast
Jochen Schopohl
@en
Jochen Schopohl
@es
Jochen Schopohl
@nl
Jochen Schopohl
@sl
P106
P21
P31
P496
0000-0003-3591-3101